Carcass characteristics and meat quality of finishing gilts fed diets with different levels of SID methionine + cystine and vitamin B6 supplementation

This study was carried out to evaluate the effects of different levels of standardized ileal digestible (SID) methionine + cystine (Met + Cys) and vitamin B6 supplementation on the carcass characteristics and longissimus lumborum (LL) quality in gilts from 75 to 100 kg. Fifty-six gilts were used (Talent x Topigs 20), with an initial average body weight of 75.06 ± 1.68 kg, allotted in a completely randomized block design arranged in a 2×4 factorial scheme, composed of two vitamin B6 supplementation levels (1.58 and 3.58 mg/kg) and four levels of SID Met + Cys (0.370, 0.470, 0.570, and 0.670%), with seven replicates and one animal per experimental unit. No interactions (P > 0.05) between vitamin B6 supplementation and SID Met + Cys levels were observed. The levels of SID Met + Cys and vitamin B6 supplementation did not affect the carcass characteristics. Thawing loss increased linearly, and a quadratic effect was observed for cooking loss and shear force of the LL when dietary SID Met + Cys levels increased. The highest cooking loss (27.29%) and shear force (21.58 N) were estimated at 0.528 and 0.539% SID Met + Cys levels, respectively. The dietary SID Met + Cys requirement for gilts (75–100 kg) did not exceed 10.60 g/day (0.37%), based on carcass characteristics and meat quality parameters, and was not affected by vitamin B6 supplementation

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection